Top MarketRank™ StocksTop MarketRank™NASDAQ:BMRN BioMarin Pharmaceutical (BMRN) Stock Price, News & Analysis $69.98 -0.55 (-0.78%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About BioMarin Pharmaceutical Stock (NASDAQ:BMRN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BMRN alerts:Sign Up Key Stats Today's Range$69.41▼$70.3750-Day Range$68.16▼$93.8452-Week Range$67.75▼$99.56Volume1.54 million shsAverage Volume1.85 million shsMarket Capitalization$13.29 billionP/E Ratio52.62Dividend YieldN/APrice Target$96.40Consensus RatingModerate Buy Company OverviewBioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.Read More… 24/7 Automated Profits in Crypto (Ad)The 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But here’s the thing: most people won’t be able to keep up with the pace of the market. That’s why I want to tell you about WaveBot – an automated trading tool created by my good friends Joel and Adam.Register for the FREE Workshop Now & get $10 in Bitcoin BioMarin Pharmaceutical Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks100th Percentile Overall ScoreBMRN MarketRank™: BioMarin Pharmaceutical scored higher than 100% of companies evaluated by MarketBeat, and ranked 2nd out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBioMarin Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 14 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageBioMarin Pharmaceutical has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BioMarin Pharmaceutical's stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth34.31% Earnings GrowthEarnings for BioMarin Pharmaceutical are expected to grow by 34.31% in the coming year, from $2.39 to $3.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioMarin Pharmaceutical is 52.62, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 130.00.Price to Earnings Ratio vs. SectorThe P/E ratio of BioMarin Pharmaceutical is 52.62, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 142.79.Price to Earnings Growth RatioBioMarin Pharmaceutical has a PEG Ratio of 0.81. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioBioMarin Pharmaceutical has a P/B Ratio of 2.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about BioMarin Pharmaceutical's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.78% of the outstanding shares of BioMarin Pharmaceutical have been sold short.Short Interest Ratio / Days to CoverBioMarin Pharmaceutical has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioMarin Pharmaceutical has recently decreased by 12.15%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioMarin Pharmaceutical does not currently pay a dividend.Dividend GrowthBioMarin Pharmaceutical does not have a long track record of dividend growth. Sustainability and ESG3.3 / 5Environmental Score-2.93 Percentage of Shares Shorted2.78% of the outstanding shares of BioMarin Pharmaceutical have been sold short.Short Interest Ratio / Days to CoverBioMarin Pharmaceutical has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioMarin Pharmaceutical has recently decreased by 12.15%, indicating that investor sentiment is improving significantly. News and Social Media3.1 / 5News Sentiment0.61 News SentimentBioMarin Pharmaceutical has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for BioMarin Pharmaceutical this week, compared to 8 articles on an average week.Search Interest17 people have searched for BMRN on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.MarketBeat Follows13 people have added BioMarin Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 117% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioMarin Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.85% of the stock of BioMarin Pharmaceutical is held by insiders.Percentage Held by Institutions98.71% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioMarin Pharmaceutical's insider trading history. Receive BMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address BMRN Stock News Headlines3 Oversold Stocks with Big RSI Rebound Potential (BMRN)Everybody loves finding a bargain or getting a good deal, and it's no different when it comes to stocks. The RSI indicator is a great way to find them.October 3, 2024 | marketbeat.comBioMarin Pharmaceutical (BMRN) to Release Quarterly Earnings on TuesdayOctober 22 at 6:11 AM | americanbankingnews.com24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But here’s the thing: most people won’t be able to keep up with the pace of the market. That’s why I want to tell you about WaveBot – an automated trading tool created by my good friends Joel and Adam.October 24, 2024 | Crypto Swap Profits (Ad)BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ETOctober 16, 2024 | prnewswire.comBiomarin Pharmaceutical (NASDAQ:BMRN) Stock, Guidance And ForecastOctober 15, 2024 | benzinga.comBioMarin Pharmaceutical (NASDAQ:BMRN) Earns Outperform Rating from Raymond JamesOctober 14, 2024 | americanbankingnews.com3 Biotech Stocks With Huge Upside Based on Analyst Price TargetsOctober 9, 2024 | stocknews.comAnalysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Tandem Diabetes Care (TNDM) and BioMarin Pharmaceutical (BMRN)October 4, 2024 | markets.businessinsider.comSee More Headlines BMRN Stock Analysis - Frequently Asked Questions How have BMRN shares performed this year? BioMarin Pharmaceutical's stock was trading at $96.42 at the start of the year. Since then, BMRN shares have decreased by 27.4% and is now trading at $69.98. View the best growth stocks for 2024 here. How were BioMarin Pharmaceutical's earnings last quarter? BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced its quarterly earnings results on Monday, August, 5th. The biotechnology company reported $0.77 EPS for the quarter, topping analysts' consensus estimates of $0.38 by $0.39. The biotechnology company had revenue of $712.03 million for the quarter, compared to analysts' expectations of $660.51 million. BioMarin Pharmaceutical had a trailing twelve-month return on equity of 6.91% and a net margin of 9.91%. Who are BioMarin Pharmaceutical's major shareholders? Top institutional shareholders of BioMarin Pharmaceutical include Swedbank AB (0.20%), Handelsbanken Fonder AB (0.07%), Assenagon Asset Management S.A. (0.06%) and Covea Finance (0.04%). Insiders that own company stock include Jean Jacques Bienaime, Henry J Fuchs, Richard A Meier, Jeffrey Robert Ajer, Brian Mueller, George Eric Davis, Charles Greg Guyer, V Bryan Lawlis, Erin Burkhart, Mark J Alles and Dennis Slamon. View institutional ownership trends. How do I buy shares of BioMarin Pharmaceutical? Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BioMarin Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), Incyte (INCY), NVIDIA (NVDA), Meta Platforms (META), First Solar (FSLR), (MDVN) (MDVN) and Broadcom (AVGO). Company Calendar Last Earnings8/05/2024Today10/23/2024Next Earnings (Confirmed)10/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:BMRN CUSIP09061G10 CIK1048477 Webwww.bmrn.com Phone(415) 506-6700Fax415-382-7889Employees3,401Year Founded1997Price Target and Rating Average Stock Price Target$96.40 High Stock Price Target$122.00 Low Stock Price Target$72.00 Potential Upside/Downside+37.8%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage22 Analysts Profitability EPS (Most Recent Fiscal Year)$1.07 Trailing P/E Ratio52.62 Forward P/E Ratio29.28 P/E Growth0.81Net Income$167.65 million Net Margins9.91% Pretax Margin11.54% Return on Equity6.91% Return on Assets5.07% Debt Debt-to-Equity Ratio0.11 Current Ratio3.05 Quick Ratio1.95 Sales & Book Value Annual Sales$2.59 billion Price / Sales5.13 Cash Flow$1.79 per share Price / Cash Flow39.02 Book Value$26.29 per share Price / Book2.66Miscellaneous Outstanding Shares189,880,000Free Float186,367,000Market Cap$13.29 billion OptionableOptionable Beta0.31 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report This page (NASDAQ:BMRN) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.